[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336685-105":59,"doc-detail-336685-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-and-challenges-in-the-origin-and-evolution-of-ovarian-cancer-organoids-review","Advances and challenges in the origin and evolution of ovarian cancer organoids - review","","Advances and challenges in the origin and evolution of ovarian cancer organoids examines epithelial ovarian cancer as a major threat to women’s health, highlighting low five-year survival and poor prognosis for advanced FIGO III–IV disease. It reviews how standard surgery and platinum-based chemotherapy still face high recurrence and chemoresistance, motivating new 3D patient-derived organoid (PDO) models. Organoids reproduce key morphological, histological, and genetic features, enabling prediction of treatment response and support for personalized therapeutic strategy development. The review also discusses organoid applications in drug evaluation, modeling disease progression and disseminated states, and uncovering mechanisms of drug resistance to inform more effective interventions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-and-challenges-in-the-origin-and-evolution-of-ovarian-cancer-organoids-review/336685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-and-challenges-in-the-origin-and-evolution-of-ovarian-cancer-organoids-review/336685.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are ovarian cancer organoids important for research?","Question",{"text":112,"@type":113},"Organoids can accurately recapitulate key morphological, histological, and genetic features of ovarian cancer, and they provide valuable preclinical tools for predicting patient treatment responses and guiding personalized therapeutic strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical problems drive the need for organoid-based models?",{"text":117,"@type":113},"Epithelial ovarian cancer has a low five-year survival rate and advanced-stage cases have poor prognosis. Even after surgical resection and platinum-based chemotherapy, many patients experience recurrence and develop chemoresistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do organoids contribute to drug evaluation and therapy development?",{"text":121,"@type":113},"Organoids serve as versatile platforms for testing drug combinations and novel candidates. They also help model disease progression and dissemination and support investigation of mechanisms underlying drug resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336685,1790180485,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 16 August 2024 DOI 10.3389/fonc.2024.1429141  \nOPEN ACCESS  \nEDITED BY  \nJianfeng Guo,  \nHuazhong University of Science and Technology, China  \nREVIEWED BY Yu Shu,  \nShanghai Jiao Tong University, China Jia-Ling Ruan,  \nUniversity of Oxford, United Kingdom Jing Wang,  \nCentral South University, China  \n*CORRESPONDENCE Rutie Yin  \n [yinrutie@scu.edu.cn](yinrutie@scu.edu.cn)  \nRECEIVED 07 May 2024  \nACCEPTED 30 July 2024  \nPUBLISHED 16 August 2024  \nCITATION  \nZhang M, Yin R and Li K (2024) Advances and challenges in the origin and evolution of ovarian cancer organoids.  \nFront. Oncol. 14:1429141 .  \ndoi: 10.3389/fonc.2024.1429141  \nCOPYRIGHT  \n© 2024 Zhang, Yin and Li. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances and challenges in the origin and evolution of ovarian cancer organoids  \nMengpei Zhang 1,2, Rutie Yin 1,2* and Kemin Li 1,2  \n1 Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China, 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China  \nDespite advancements in cancer research, epithelial ovarian cancer remains a leading threat to women’s health with a low ﬁve-year survival rate of 48% . Prognosis for advanced cases, especially International Federation of Gynecology and Obstetrics (FIGO) III-IV, is poor. Standard care includes surgical resection and platinum-based chemo, but 70-80% face recurrence and chemoresistance. In recent years, three-dimensional (3D) cancer models, especially patients-derived organoids (PDOs), have revolutionized cancer research for personalized treatment. By transcending the constraints of conventional models, organoids accurately recapitulate crucial morphological, histological, and genetic characteristics of diseases, particularly in the context of ovarian cancer. The extensive potential of ovarian cancer organoids is explored, spanning from foundational theories to cutting-edge applications. As potent preclinical models, organoids offer invaluable tools for predicting patient treatment responses and guiding the development of personalized therapeutic strategies. Furthermore, in the arena of drug evaluation, organoids demonstrate their unique versatility as platforms, enabling comprehensive testing of innovative drug combinations and novel candidates, thereby pioneering new avenues in pharmaceutical research. Notably, organoids mimic the dynamic progression of ovarian cancer, from inception to systemic dissemination, shedding light on intricate and subtle disease mechanisms, and providing crucial insights. Operating at an individualized level, organoids also unravel the complex mechanisms underlying drug resistance, presenting strategic opportunities for the development of effective treatment strategies. This review summarizes the emerging role of ovarian cancer organoids, meticulously cultivated cellular clusters within threedimensional models, as a groundbreaking paradigm in research.  \nKEYWORDS  \norganoids, patients-derived organoids, ovarian cancer, advances and challenges, review  \nAbbreviations: FIGO, International Federation of Gynecology and Obstetrics; PARP, Poly ADP-ribose polymerase; PFS, progression-free survival; 3D, three-dimensional; PDOs, patients-derived organoids; 2D, two-dimensional; PDX, patient-derived xenograft; HGSOC, high-grade serous ovarian carcinoma; HRD, homologous recombination deﬁciency; TME, tumor microenvironment; TILs, tumor-inﬁltrating lymphocytes; CAFs, cancer-associated ﬁbroblasts; ","cbCaicGCgSGOUxd6","https://ap.wps.com/l/cbCaicGCgSGOUxd6","pdf",2327184,12,"English","# Introduction\n## Current clinical challenges and standard care\n## Advances in targeted therapy and limitations\n## Rationale for ovarian cancer organoid models","[{\"question\":\"Why are ovarian cancer organoids important for research?\",\"answer\":\"Organoids can accurately recapitulate key morphological, histological, and genetic features of ovarian cancer, and they provide valuable preclinical tools for predicting patient treatment responses and guiding personalized therapeutic strategies.\"},{\"question\":\"What clinical problems drive the need for organoid-based models?\",\"answer\":\"Epithelial ovarian cancer has a low five-year survival rate and advanced-stage cases have poor prognosis. Even after surgical resection and platinum-based chemotherapy, many patients experience recurrence and develop chemoresistance.\"},{\"question\":\"How do organoids contribute to drug evaluation and therapy development?\",\"answer\":\"Organoids serve as versatile platforms for testing drug combinations and novel candidates. They also help model disease progression and dissemination and support investigation of mechanisms underlying drug resistance.\"}]","Advances and challenges in the origin and evolution of ovarian cancer organoids - review | PDF",1790016156,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e14a287442379c5222836aefe974182b.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bff09ee044ff06370d01456d422b123c.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95e22a2554ebddbcc5646ff1aebd3242.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/488c6fd5e1c3e2b2bc9f07261af8ead6.webp",980,1385]